BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33397398)

  • 21. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
    J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
    Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
    Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
    Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
    Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
    Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
    Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
    Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
    Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
    Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
    Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
    Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
    Chow PM; Liu SH; Chang YW; Kuo KL; Lin WC; Huang KH
    Cancer Lett; 2020 Feb; 471():27-37. PubMed ID: 31812697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
    Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
    Ge H; Yao Y; Jiang Y; Wu X; Wang Y
    Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
    Ghezzi C; Wong A; Chen BY; Ribalet B; Damoiseaux R; Clark PM
    Nat Commun; 2019 Nov; 10(1):5444. PubMed ID: 31784510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
    Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
    Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.
    Xia L; Zheng Z; Liu JY; Chen YJ; Ding J; Hu GS; Hu YH; Liu S; Luo WX; Xia NS; Liu W
    Cancer Immunol Res; 2021 Jun; 9(6):707-722. PubMed ID: 33875483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK7 inhibitors as anticancer drugs.
    Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
    Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
    Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.